Skip to content
PubMed This is a summary of 57 peer-reviewed journal articles Updated
Neurology

Autosomal Dominant Cerebellar Ataxia-Deafness-Narcolepsy Syndrome (ADCA-DN): A Patient Guide

At a Glance

ADCA-DN is a very rare inherited disorder caused by a harmful change in the DNMT1 gene that gradually affects balance, hearing, and daytime alertness. Although no cure currently stops progression, coordinated care can manage symptoms, improve safety, and help patients maintain independence.

Autosomal Dominant Cerebellar Ataxia-Deafness-Narcolepsy Syndrome (ADCA-DN) is a very rare neurodegenerative disorder that typically begins to show its first signs in adulthood, often during a person’s 40s or 50s [1]. Because it is so rare, many families spend years searching for answers, only to find that their symptoms are connected by a single underlying genetic cause. The condition is defined by a “core triad” of symptoms that affect movement, hearing, and sleep: cerebellar ataxia (problems with balance and coordination), sensorineural hearing loss (progressive deafness), and excessive daytime sleepiness (which a sleep specialist evaluates to determine if it meets the formal diagnosis of narcolepsy) [2][3]. While these three features are the hallmark of the disease, they do not always appear at the same time, and their severity can vary significantly even among members of the same family [4].

The root of ADCA-DN lies in the DNMT1 gene, which provides instructions for an enzyme that helps manage how your DNA is “read” by your cells [5]. When this gene has a pathogenic mutation, the enzyme cannot correctly regulate a process called DNA methylation, leading to a gradual breakdown of nerve cells in specific parts of the brain and nervous system [6]. This condition is inherited in an autosomal dominant pattern, meaning that an affected parent has a 50% chance of passing the mutation to each of their children [2]. ADCA-DN is also recognized as part of a broader spectrum of disorders caused by the same gene, including a related condition called HSAN1E, which often features more prominent nerve pain or loss of sensation in the feet [4][7].

Living with ADCA-DN requires a proactive and multidisciplinary approach to care. Because there is currently no cure to stop the progression of the disease, the primary goal of treatment is to manage symptoms, maintain independence, and ensure safety [8]. This involves a team of specialists—including neurologists, sleep doctors, audiologists, and physical therapists—working together to address each symptom as it arises [9]. For many, this means using hearing aids or cochlear implants to stay connected, taking medications to manage daytime sleepiness, and engaging in physical therapy to maintain balance and prevent falls [10][11][12].

While the progressive nature of ADCA-DN can feel daunting, receiving a clear diagnosis is a powerful step toward taking control of your health. It allows you and your family to move from the uncertainty of unexplained symptoms to a focused plan for the future. With the support of a specialized medical team and genetic counseling, patients and their families can make informed decisions about their care, manage the impact of the condition on their daily lives, and navigate the journey ahead with clarity and purpose [8][2].

Common questions in this guide

What are the main symptoms of ADCA-DN?
ADCA-DN classically affects three areas: balance and coordination because of cerebellar ataxia, hearing through progressive sensorineural hearing loss, and wakefulness through excessive daytime sleepiness. These features may develop at different times, and their severity can vary among relatives.
What causes ADCA-DN, and can it run in families?
ADCA-DN is caused by a harmful change in the DNMT1 gene, which affects how cells regulate DNA and can lead to gradual nerve-cell damage. It follows an autosomal dominant pattern, so a parent with the mutation has a 50% chance of passing it to each child.
Which tests and specialists help evaluate ADCA-DN?
Evaluation may involve a neurologist, sleep specialist, audiologist, and physical therapist, with genetic counseling for family testing and planning. Formal balance testing, hearing evaluation, and a sleep study can help document current function and establish a baseline.
Is there a cure for ADCA-DN?
There is currently no cure that stops ADCA-DN from progressing. Treatment focuses on managing symptoms, maintaining independence, and reducing safety risks with options such as hearing aids or cochlear implants, medicines for daytime sleepiness, and physical therapy.
Should relatives of someone with ADCA-DN consider genetic counseling?
Because ADCA-DN can be passed through families in an autosomal dominant pattern, biological relatives may want to discuss their individual risk with a genetic counselor. Counseling can explain testing options, possible results, and implications for relatives and future family planning.
How can daily activities be made safer with ADCA-DN?
Safety planning should be based on the person’s current balance and alertness. The care team can recommend home or workplace changes and physical therapy strategies to help prevent falls and address unpredictable daytime sleepiness.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specialist on my team is currently acting as the primary coordinator for my care across neurology, audiology, and sleep medicine?
  2. 2.What objective tests, such as a formal balance assessment or a sleep study, should we use to establish my current baseline?
  3. 3.Since this condition is autosomal dominant, can you provide a summary or a referral for a genetic counselor to discuss testing for my biological relatives?
  4. 4.What specific safety modifications do you recommend for my home or workplace based on my current balance and alertness levels?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Cerebellar Ataxia-deafness-narcolepsy (ADCA) syndrome. Description of a variable family phenotype.

    Abenza-Abildúa MJ, Palmí-Cortés I, Ojeda-Ruiz de Luna J, et al.

    Acta neurologica Belgica 2025; (125(5)):1395-1399 doi:10.1007/s13760-025-02776-1.

    PMID: 40285998
  2. 2

    Identification of a methylation profile for DNMT1-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy.

    Kernohan KD, Cigana Schenkel L, Huang L, et al.

    Clinical epigenetics 2016; (8()):91 doi:10.1186/s13148-016-0254-x.

    PMID: 27602171
  3. 3

    Cataplexy and ataxia: red flags for the diagnosis of DNA methyltransferase 1 mutation.

    Postiglione E, Antelmi E, Pizza F, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2020; (16(1)):143-147 doi:10.5664/jcsm.8140.

    PMID: 31957642
  4. 4

    Cerebellar Ataxia as a Common Clinical Presentation Associated with DNMT1 p.Y511H and a Review of the Literature.

    Kikuchi JK, Nagashima Y, Mano T, et al.

    Journal of molecular neuroscience : MN 2021; (71(9)):1796-1801 doi:10.1007/s12031-020-01784-5.

    PMID: 33433851
  5. 5

    Defects of mutant DNMT1 are linked to a spectrum of neurological disorders.

    Baets J, Duan X, Wu Y, et al.

    Brain : a journal of neurology 2015; (138(Pt 4)):845-61 doi:10.1093/brain/awv010.

    PMID: 25678562
  6. 6

    Disease-Associated Mutations G589A and V590F Relieve Replication Focus Targeting Sequence-Mediated Autoinhibition of DNA Methyltransferase 1.

    Dolen EK, McGinnis JH, Tavory RN, et al.

    Biochemistry 2019; (58(51)):5151-5159 doi:10.1021/acs.biochem.9b00749.

    PMID: 31804802
  7. 7

    Hummingbird sign in a patient with DNMT1-related disorder.

    Tamura M, Sugiyama A, Hirano S, et al.

    Neurocase 2025; (31(5)):239-244 doi:10.1080/13554794.2025.2560858.

    PMID: 40937613
  8. 8

    Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options.

    Bremova-Ertl T, Hofmann J, Stucki J, et al.

    Cells 2023; (12(18)) doi:10.3390/cells12182314.

    PMID: 37759536
  9. 9

    Epidemiology of Cerebellar Diseases and Therapeutic Approaches.

    Salman MS

    Cerebellum (London, England) 2018; (17(1)):4-11 doi:10.1007/s12311-017-0885-2.

    PMID: 28940047
  10. 10

    DNMT1-associated sensory neuropathy and cerebellar ataxia: A novel variant and review of genotype-phenotype correlation.

    Menon PJ, Bogdanova-Mihaylova P, McDermott G, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):508-512 doi:10.1111/jns.12560.

    PMID: 37199681
  11. 11

    European guideline and expert statements on the management of narcolepsy in adults and children.

    Bassetti CLA, Kallweit U, Vignatelli L, et al.

    European journal of neurology 2021; (28(9)):2815-2830 doi:10.1111/ene.14888.

    PMID: 34173695
  12. 12

    Effects of physiotherapy on degenerative cerebellar ataxia: a systematic review and meta-analysis.

    Matsugi A, Bando K, Kondo Y, et al.

    Frontiers in neurology 2024; (15()):1491142 doi:10.3389/fneur.2024.1491142.

    PMID: 39866519

This page provides general information about ADCA-DN and does not replace medical advice. A neurologist, genetic counselor, sleep specialist, or audiologist can help interpret symptoms and plan care for your situation.

Get notified when new evidence is published on Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.